Practice Management
Researchers found the oral antiviral drug nirmatrelvir/ritonavir (Paxlovid) is safe for kids as young as age 6 with mild/moderate COVID-19 who were at increased risk for severe disease, as published in Pediatrics. Of the in 75 children in the international study, 81% had 1 risk factor for severe COVID-19, most commonly obesity (49%) or chronic lung disease (40%). Additionally, 56% were unvaccinated. Children aged 6–17 years who weighed 40 kg or more received 300 mg …
Read More
In December 2023, drug manufacturer Pfizer changed its strategic sales approach for nirmatrelvir/ritonavir (Paxlovid) by shifting to commercial sales in lieu of providing the COVID-19 antiviral drug at no-cost to patients exclusively through the federal government, according to Kaiser Health News. Some patients, such as those who are uninsured or enrolled in Medicare, Medicaid, may qualify for free prescription fills, but they need to work through an application process. What’s concerning is that nirmatrelvir/ritonavir has …
Read More
Fever: To Treat or Not to Treat? Distinguishing Viral from Bacterial Conjunctivitis Scapular Fractures and Blunt Chest Trauma in Children Sterile vs Nonsterile Gloves for Laceration Repair Bronchiolitis Care: An Update Antibiotic Stewardship and Children Post Paxlovid Rebound Ivan Koay MBChB, FRNZCUC, MD What Are the Consequences of Treating Adult Fever? Take-home point: Fever therapy in adults does not seem to affect the risk of death and serious adverse events. Citation: Holgersson J, Ceric A, …
Read More